Table 3 Efficacy results of candidate vaccines for passive immunization against respiratory syncytial virus
Class | Vaccine structure | Clinical trial phase | Results |
|---|---|---|---|
Human polyclonal | |||
RSV IVIG | Passed clinical trials | - 40.7% relative reduction in hospitalization compared to placebo - 63.4% relative reduction in hospitalization compared to placebo | |
Humanized monoclonal Ig[36] | Palivizumab | Passed clinical trials | - 54.7% relative reduction in hospitalisation compared to placebo |
Humanized monoclonal Ig[37] | Motavizumab | III | - 50% relative reduction in medically attended LRI compared to Palivizumab. - 26% relative reduction in hospitalisation compared to Palivizumab. |